The Nonalcoholic Steatohepatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nonalcoholic Steatohepatitis pipeline products will significantly revolutionize the Nonalcoholic Steatohepatitis market dynamics.
DelveInsight’s “Nonalcoholic Steatohepatitis Diagnostics Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the Nonalcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The Nonalcoholic Steatohepatitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Some of the key facts of the Nonalcoholic Steatohepatitis Market Report:
-
Nonalcoholic Steatohepatitis market size was highest in the United States among the 7MM countries, accounting for approximately USD 1.5 billion in 2023
-
In November 2024, Novo Nordisk announced positive results for semaglutide in treating Nonalcoholic Steatohepatitis; In October 2024, Sagimet Biosciences announced successful end-of-Phase 2 FDA interactions for denifanstat; In March 2024, Madrigal Pharmaceuticals’ REZDIFFRA (resmetirom) received accelerated FDA approval
-
Nonalcoholic Steatohepatitis Companies: Madrigal Pharmaceuticals, Novo Nordisk A/S, 89bio, Inc., Akero Therapeutics, Inc., Galectin Therapeutics, Sagimet Biosciences, Inventiva Pharma
-
Nonalcoholic Steatohepatitis Therapies: REZDIFFRA (resmetirom), Pegozafermin (BIO89-100), Efruxifermin (EFX), Belapectin, Semaglutide, Denifanstat
Nonalcoholic Steatohepatitis Overview
Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is a common chronic liver disease defined as liver inflammation and damage caused by buildup of fat in the liver. NASH is similar to the kind of liver disease caused by long-term, heavy drinking. If someone has NASH, their liver has a high percentage of fat with swollen sustained damage, causing fibrosis, or scarring. If the scarring is remarkably significant, it may lead to cirrhosis, a condition that causes permanent liver damage.
According to the American Liver Foundation, the exact cause of NAFLD is not known. The likely cause to develop NAFLD – either simple fatty liver or NASH – is in case of overweight or obesity, type 2 diabetes or pre-diabetes, abnormal levels of fats reported in blood, and others.
Get a Free sample for the Nonalcoholic Steatohepatitis Market Report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Nonalcoholic Steatohepatitis Market
The dynamics of the Nonalcoholic Steatohepatitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2025-2034. The Nonalcoholic Steatohepatitis market size in the 7MM was approximately USD 2 billion and is projected to increase during the forecast period. The market has historically been constrained by the lack of FDA-approved therapies, but the recent approvals and pipeline advancements are poised to significantly expand market opportunities. With the emergence of REZDIFFRA as the first FDA-approved therapy for NASH and multiple candidates in late-stage development, the market landscape is undergoing transformative change that will reshape treatment paradigms and patient outcomes.
Nonalcoholic Steatohepatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Nonalcoholic Steatohepatitis Epidemiology Segmentation:
The Nonalcoholic Steatohepatitis market report offers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Nonalcoholic Steatohepatitis Prevalence Cases
-
Nonalcoholic Steatohepatitis Diagnosed Prevalence Cases
-
Nonalcoholic Steatohepatitis Gender-specific Diagnosed Prevalence Cases
-
Nonalcoholic Steatohepatitis Severity-specific Diagnosed Prevalence Cases
Download the report to understand which factors are driving Nonalcoholic Steatohepatitis epidemiology trends @ Nonalcoholic Steatohepatitis Epidemiological Insights
Nonalcoholic Steatohepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nonalcoholic Steatohepatitis market or expected to get launched during the study period. The analysis covers Nonalcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. For example, Lanifibranor/IVA337 in the US is expected to be launched by 2027 with a peak share of 2.9%. HPG1860 is anticipated to take 7 years to peak with slow-medium uptake.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Nonalcoholic Steatohepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Nonalcoholic Steatohepatitis treatment, visit @ Nonalcoholic Steatohepatitis Medications
Nonalcoholic Steatohepatitis Therapies and Key Companies
-
REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
-
Pegozafermin (BIO89-100): 89bio, Inc.
-
Efruxifermin (EFX): Akero Therapeutics, Inc.
-
Belapectin: Galectin Therapeutics
-
Semaglutide: Novo Nordisk A/S
-
Denifanstat: Sagimet Biosciences
-
Lanifibranor/IVA337: Inventiva Pharma
-
VK2809: Viking Therapeutics
Nonalcoholic Steatohepatitis Market Drivers
-
Rising Prevalence of Obesity and Metabolic Syndrome: Increasing obesity, diabetes, and metabolic syndrome prevalence are driving a rise in diagnosed NASH cases, with projections indicating continued growth through 2034
-
Lack of Prior Therapeutic Options: Until mid-March 2024, the Nonalcoholic Steatohepatitis Therapeutics Market Landscape lacked FDA, EMA, or PMDA-approved medications, relying primarily on lifestyle adjustments, making the approval of REZDIFFRA a significant breakthrough
-
Growing Awareness and Improved Diagnostics: Growing awareness, improved diagnostic tools, and rising lifestyle-related risk factors are key drivers of market expansion
-
Emerging Pipeline Products: The emergence of multiple Phase II and Phase III candidates targeting various pathways (FGF21 agonists, THR-ß agonists, antifibrotic agents) is expected to significantly revolutionize the market dynamics and expand treatment options
Nonalcoholic Steatohepatitis Market Barriers
-
Reimbursement and Pricing Challenges: Ensuring adequate reimbursement coverage and establishing competitive pricing strategies for novel therapies remains a significant barrier, particularly in European markets
-
Diagnostic Complexity: The difficulty in diagnosing NASH accurately without liver biopsy limits early detection and treatment initiation, constraining market growth
-
High Development Costs: The complexity of NASH pathogenesis and the need for comprehensive clinical trials to demonstrate efficacy and safety of new therapies result in substantial R&D investments and prolonged development timelines
-
Patient Awareness Gaps: Despite increasing prevalence, many patients remain unaware of their NASH status, limiting the addressable patient population for marketed and emerging therapies
Scope of the Nonalcoholic Steatohepatitis Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
-
Key Nonalcoholic Steatohepatitis Companies: Madrigal Pharmaceuticals, Novo Nordisk A/S, Eli Lilly and Company, 89bio, Inc., Akero Therapeutics, Inc., Galectin Therapeutics, Sagimet Biosciences, Inventiva Pharma, Zydus Therapeutics, Terns, Inc., Intercept Pharmaceuticals, Enyo Pharma
-
Key Nonalcoholic Steatohepatitis Therapies: REZDIFFRA (resmetirom), Pegozafermin (BIO89-100), Efruxifermin (EFX), Belapectin, Semaglutide, Denifanstat, Lanifibranor, VK2809
-
Nonalcoholic Steatohepatitis Therapeutic Assessment: Nonalcoholic Steatohepatitis current marketed and Nonalcoholic Steatohepatitis emerging therapies
-
Nonalcoholic Steatohepatitis Market Dynamics: Nonalcoholic Steatohepatitis market drivers and Nonalcoholic Steatohepatitis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Nonalcoholic Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Nonalcoholic Steatohepatitis Market Access and Reimbursement
Discover more about therapies set to grab major Nonalcoholic Steatohepatitis market share @ Nonalcoholic Steatohepatitis Treatment Landscape
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary
-
Nonalcoholic Steatohepatitis Market Overview at a Glance
-
Epidemiology and Market Forecast Methodology
-
Key Events
-
Nonalcoholic Steatohepatitis Background and Overview
-
Nonalcoholic Steatohepatitis Treatment
-
Nonalcoholic Steatohepatitis Epidemiology and Patient Population in the 7MM
-
Nonalcoholic Steatohepatitis Patient Journey
-
Nonalcoholic Steatohepatitis Marketed Drug
-
Nonalcoholic Steatohepatitis Emerging Drugs
-
Nonalcoholic Steatohepatitis: 7MM Analysis
-
Unmet needs
-
SWOT Analysis
-
KOL Views
-
Market Access and Reimbursement
-
Appendix
-
DelveInsight Capabilities
-
Disclaimer
-
About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services